WO2000016753A2 - Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika - Google Patents
Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika Download PDFInfo
- Publication number
- WO2000016753A2 WO2000016753A2 PCT/DE1999/002944 DE9902944W WO0016753A2 WO 2000016753 A2 WO2000016753 A2 WO 2000016753A2 DE 9902944 W DE9902944 W DE 9902944W WO 0016753 A2 WO0016753 A2 WO 0016753A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivatives
- methyluracil
- side effects
- nucleobases
- nucleosides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
Definitions
- nucleosides Use of nucleosides, nucleobases and their derivatives to reduce thrombocytopenic side effects of cytostatics
- the invention relates to the use of nucleosides, nucleobases and their derivatives, in particular 6-methyluracil, for reducing thrombocytopenic side effects of cytostatics and combination preparations of nucleosides, nucleobases and their derivatives and cytostatics, in particular a combination preparation which contains at least one cytostatic and 6-methyluracil .
- the cytostatics used for the treatment of tumor diseases in addition to their desired anti-tumor activity, generally have toxic side effects which limit the dose. Since the dose-effect curve for cytostatics is particularly steep, it would be advisable to choose the highest possible dose, but this cannot generally be applied because of the serious side effects that then occur.
- hemopoietic growth factors eg for the stem cells of granulocytes and macrophages
- the duration of the leukopenia period and thus the risk of infection could be reduced and the therapy optimized by increasing the dose of the cytostatics (F. Hansen : Hemopoietic growth and inhibitory factors in treatment of malignancies. A review. Acta Oncol. 34, 453-68 (1995)).
- ERSA72B TT (RULE 26) The situation is different with thrombocytopenia. This is e.g. B. especially with new cytostatics, such as the platinum derivatives, for. B. Carboplatin, a particularly serious side effect (eg JF Delaloy, L. Tran, S. Leyvraz, J. Bauer, P. De-Grandl: Intraperitoneal carboplatin in advanced ovarian carcinoma. Gynecol-Obstetrics-Rundschau 33, 25-30 (1993 ); K. Bertelsen, L. Basthold: High-dose platinium chemotherapy in advanced ovarian cancer. Gynecol-Oncol. 44, 79-82 (1992)).
- new cytostatics such as the platinum derivatives
- B. Carboplatin a particularly serious side effect (eg JF Delaloy, L. Tran, S. Leyvraz, J. Bauer, P. De-Grandl: Intraperitoneal carboplatin in advanced ova
- thrombocytopenia Attempts to limit the time and severity of thrombocytopenia through adjuvant drug administration are e.g. Currently still in the experimental stage. In analogy to the procedure for leukocytes, the growth factor for thrombocyte stem cells, thrombopoietin, is being experimentally tested. IL 2 is used in the same way (R. Hoffman, MW Long: Control of thrombocytoiesis. Cancer-Treat-Res. 80, 25-48 (1995); TP. McDonald: Thrombopoietin. Its biology, clinical aspects and possibilities. Am -J- Pediatr-Hematol-Oncol. 14, 8-21 (1992).
- nucleobases, nucleosides and their derivatives had been shown to stimulate the proliferation of stem cells from granulocytes and macrophages and their regeneration after cytostatica treatment (Endoxan) (P. Langen, H. Schunk, B. Hunger, M. Schutt , OD Laerum: Adherent-cell-dependent stimulation of CFU-GM by nucleobases, nucleosides, their analogues and the hemoregulatory peptide dimer. Exp. Hematol. 20, 196-200 (1993). This was associated with a drastic reduction in the lethal effect highly toxic cans.
- 6-methyluracil A particularly suitable representative of the substance group mentioned is 6-methyluracil. It has surprisingly been found that 6-methyluracil and other representatives of compounds of the formula I also reduce the thrombopenia caused by cytostatics. Such an effect could not be expected based on our own or literature findings.
- R x OH or NH 2
- R 2 H or alkyl
- R 3 H, alkyl or COOH
- R 4 H or optionally substituted deoxyribosyl
- -ribosyl or -arabinosyl mean.
- 6-Methyluracil can be used orally, cheaply and side effects have so far neither been observed by own experiments nor described in the literature. According to the results available to date, its use in combination with cytostatics is an important contribution to optimizing cancer chemotherapy.
- the preferred doses for 6-methyluracil are 150 to 600 mg / kg • day, it being shown that a dose of 300 mg / kg • day works significantly better than half, while a further doubling 600 mg / kg • Day does not lead to any clear improvements. A dose of 300 mg / kg is therefore particularly preferred. Day 6-
- REPLACEMENT BILL (RULE 26) Methyluracil applied. 6-Methyluracil is preferably used orally, although it can also be added to a drink.
- the invention also relates to a combination preparation which contains at least one cytostatic and one nucleoside, a nucleobase or derivatives thereof of the general formula I.
- R x OH or NH 2
- R 2 H or alkyl
- R 3 H, alkyl or COOH
- R ⁇ H or optionally substituted deoxyribosyl -ribosyl or -arabinosyl,
- the combination preparation contains carboplatin with auxiliaries, carriers and additives which are customary per se and 6-methyluracil also with auxiliaries, carriers and additives which are customary per se.
- mice Female B6D2F1 mice (8 / experimental group) were treated with carboplatin ip one day after inoculating Lewis lung carcinoma cells. One test group each received 100, 150 or 175 mg / kg, the highest dose corresponding approximately to an LD 40 . Further carboplatin-treated test groups received an addition of 2.4 mg / ml 6-methyluracil in the drinking water normally administered. Blood was drawn from the retroorbital vein in the mice 10 days after treatment with carboplatin. The platelet count was determined using a Coulter Counter.
- mice Female B6D2F1 mice (8 / experimental group) were treated with carboplatin ip one day after inoculating B16 melanoma cells. One test group each received 100 or 150 mg / kg, the highest dose corresponding approximately to an LD 10 . Further carboplatin-treated test groups received an addition of 1.2 mg / ml 6-methyluracil in the drinking water normally administered. Blood was drawn from the retroorbital vein from the mice 10 days after carboplatin treatment. The platelet count was determined using a Coulter Counter.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99969331A EP1037618A1 (de) | 1998-09-17 | 1999-09-16 | Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19842578.3 | 1998-09-17 | ||
DE1998142578 DE19842578A1 (de) | 1998-09-17 | 1998-09-17 | Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000016753A2 true WO2000016753A2 (de) | 2000-03-30 |
WO2000016753A3 WO2000016753A3 (de) | 2000-09-14 |
Family
ID=7881265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1999/002944 WO2000016753A2 (de) | 1998-09-17 | 1999-09-16 | Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1037618A1 (de) |
DE (1) | DE19842578A1 (de) |
WO (1) | WO2000016753A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002081664A2 (de) * | 2001-04-07 | 2002-10-17 | Max-Delbrück-Centrum für Molekulare Medizin | Verwendung von nucleosiden, nucleobasen und deren derivaten zur verbesserten gewinnung von adulten stammzellen |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023506A1 (de) * | 1995-02-01 | 1996-08-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside |
-
1998
- 1998-09-17 DE DE1998142578 patent/DE19842578A1/de not_active Withdrawn
-
1999
- 1999-09-16 WO PCT/DE1999/002944 patent/WO2000016753A2/de not_active Application Discontinuation
- 1999-09-16 EP EP99969331A patent/EP1037618A1/de not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023506A1 (de) * | 1995-02-01 | 1996-08-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside |
Non-Patent Citations (7)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002081664A2 (de) * | 2001-04-07 | 2002-10-17 | Max-Delbrück-Centrum für Molekulare Medizin | Verwendung von nucleosiden, nucleobasen und deren derivaten zur verbesserten gewinnung von adulten stammzellen |
WO2002081664A3 (de) * | 2001-04-07 | 2002-12-27 | Max Delbrueck Centrum | Verwendung von nucleosiden, nucleobasen und deren derivaten zur verbesserten gewinnung von adulten stammzellen |
Also Published As
Publication number | Publication date |
---|---|
WO2000016753A3 (de) | 2000-09-14 |
EP1037618A1 (de) | 2000-09-27 |
DE19842578A1 (de) | 2000-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100334051B1 (ko) | 탁산유도체를함유하는항종양조성물 | |
EP0453898B1 (de) | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Ischämien und deren Folgen | |
DE69525971T3 (de) | Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin | |
DE60118889T2 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
DE60223670T2 (de) | Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen. | |
DE60036826T2 (de) | Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs | |
DE69815310T2 (de) | Zubereitungen zur tumorbehandlung enthaltend hai-knorpelextrakte und antineoplastische mittel | |
DE60004348T2 (de) | Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate | |
DE69918819T2 (de) | Antikrebs-zusammensetzung enthaltend eine synergistische kombination bestehend aus einem anthracyclin-derivat mit einen camptothecin-derivat | |
EP0774255B1 (de) | Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen | |
DE3319347C2 (de) | ||
DE10103565B4 (de) | Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus | |
JP2001509479A (ja) | ヌクレオチド含有組成物 | |
EP0236951A2 (de) | Verwendung von Diphenylhydantoin und seinen Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Immunerkrankungen | |
EP0344880A2 (de) | Pharmazeutische Zusammensetzungen mit krebshemmender Wirkung | |
WO2000016753A2 (de) | Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika | |
EP1107751B1 (de) | Arzneimittel enthaltend platinkomplexverbindungen sowie deren verwendung | |
RU2240793C1 (ru) | Противоопухолевое средство | |
WO1996003996A1 (de) | Deuterium enthaltende pharmazeutische zusammensetzung zur abtötung von tumoren | |
JPH0681724B2 (ja) | 癌転移と増殖の予防および治療用組成物 | |
DE3134709A1 (de) | Antineoplastisch wirkende titanverbindung und diese enthaltende arzneimittel | |
DE10359828A1 (de) | CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe | |
DE10113185A1 (de) | Zusammensetzung, enthaltend einen Gallium(III)-Komplex und einen therapeutisch wirksamen Platin-Komplex | |
DE4442257A1 (de) | Sparsomycin | |
DE3935132A1 (de) | Antitumormittel, mittel zum unterdruecken von tumorzellmetastasen und verfahren zum behandeln von krebs und zum kontrollieren von tumorzellmetastasen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999969331 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1999969331 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999969331 Country of ref document: EP |